GRAIL Inc. (GRAL) Cash Flow Statement

The OCF/NI ratio has hovered between 0.64 and 0.93 in recent quarters, meaning cash outflows are consistently less than accounting losses. This suggests that while the company is burning cash, the reported net loss overstates the immediate cash drain due to significant non-cash items. However, the persistent negative OCF indicates that the business is still far from self-funding, and the quality of earnings is low as losses are driven by operational spending rather than one-time charges.

Despite accelerating revenue growth, FCF has remained deeply negative, with the most recent quarter showing a burn of $81.2M. The FCF margin has deteriorated from -2.1% in 2026Q1 to -181.6% in 2026Q2, indicating that the cost structure is not leveraging with scale. This suggests that the company is still in a heavy investment phase, and investors should monitor whether the increasing revenue can eventually outpace the fixed cost base.

Capital expenditures have been consistently below $1M per quarter, which is remarkably low for a diagnostics company. This suggests that the company's growth is not currently constrained by physical capacity, but rather by clinical validation and market adoption. However, the negative gross margins imply that the cost of goods sold is high, likely due to consumables and labor, which may require future CapEx to achieve economies of scale. The low CapEx/Revenue ratio may also indicate that the company is outsourcing manufacturing or using leased facilities, which could shift costs to operating expenses.

The working capital adjustments are relatively small compared to the overall cash burn, but they show significant quarter-to-quarter variability. This could be due to the timing of payments from self-pay patients or institutional contracts, which may not follow a consistent pattern. The positive working capital in some quarters (e.g., +$8.2M in 2026Q2) suggests that the company is collecting on receivables, but the negative swings indicate that payables or inventory management may be causing cash outflows. Investors should monitor whether the company can stabilize its working capital cycle as revenue scales.

The company has not returned any capital to shareholders, which is typical for a pre-profit biotech. The absence of dividends and buybacks indicates that management is prioritizing investment in the business, particularly in R&D and commercial expansion. However, this also means that shareholders are entirely reliant on future value creation from the Galleri test and other pipeline assets. The lack of capital returns, combined with the persistent cash burn, underscores the need for external financing or a significant inflection in profitability.

The cumulative gap between net income and operating cash flow is substantial, driven largely by the one-time spin-off charges in 2024Q2 and ongoing non-cash expenses like D&A and SBC. This divergence suggests that the company's cash burn is less severe than the income statement implies, but the underlying trend is still negative. Investors should focus on the operating cash flow trend, which has remained consistently negative, indicating that the business is not yet generating cash from its operations. The spin-off distortion is a one-time event, but the ongoing gap highlights the need for careful cash flow analysis.